Waterdrop Inc. Announces Second Quarter 2024 Unaudited Financial Results and a Special Cash Dividend
BEIJING, Sept. 4, 2024 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced its unaudited financial results for the three and six months ended June 30, 2024 and a special cash dividend. Financial and Operational Highlights for the Second Quarter of...
21st.BIO obtains self-affirmed GRAS status for its precision fermented beta-lactoglobulin: 21st.BIO customers can now enter the U.S. market with their own production using 21st.BIO technology
21st.BIO has earned a self-affirmed GRAS status for its animal-free beta-lactoglobulin ingredient, which customers can now launch in the United States market. 21st.BIO is helping customers bring products to market at an unprecedented pace, from initiation of development to market approval in under two years. 21st.BIO offers the leading production technology for BLG, based on precision fermentation technology that...
HKBU develops Chinese medicine for ulcerative colitis approved by National Medical Products Administration for clinical trial
HONG KONG, Sept. 4, 2024 /PRNewswire/ -- The Centre for Chinese Herbal Medicine Drug Development (CDD) at Hong Kong Baptist University (HKBU) has achieved a significant milestone in developing a novel Chinese herbal formulation for ulcerative colitis remission maintenance. Following a submission of Investigational New Drug application for CDD-2103 to the National Medical Products Administration (NMPA) in mid-June this year, CDD has received...
3 in 5 Aspiring Entrepreneurs in Asia Pacific Planning to Start a Small Business in the Next 18 Months – Herbalife Survey
Untapped opportunities seen in health and wellness for aspiring entrepreneurs HONG KONG, Sept. 4, 2024 /PRNewswire/ -- Herbalife, a premier health and wellness company and community, today released findings from its Asia Pacific Business of Wellness Survey, which revealed that despite concerns about the current state of the economy, more than three in five (63%) aspiring entrepreneurs in Asia Pacific plan...
Innovent Receives Fast Track Designation from the U.S. FDA for IBI363 (PD-1/IL-2α Bispecific Antibody Fusion Protein) as Monotherapy for Advanced Melanoma
SAN FRANCISCO and SUZHOU, China, Sept. 4, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its PD-1/IL-2α Bispecific Antibody Fusion...
IPAX-1 Study of TLX101 Investigational Glioblastoma Therapy Published in Neuro-Oncology Advances
MELBOURNE, Australia, Sept. 4, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Company's IPAX-1 Phase I study has been published in Neuro-Oncology Advances, confirming the safety and tolerability profile, and early efficacy of TLX101 therapy, in combination with external beam radiation therapy (EBRT) in recurrent glioblastoma...
Acepodia Enters Strategic Clinical Collaboration with Pfizer to Accelerate Development of Antibody-Cell Conjugation-Based Cell Therapies in Autoimmune Diseases
Through Pfizer Ignite, Acepodia will gain access to Pfizer's resources, scale and expertise as the company broadens the application of its platform beyond oncology into autoimmune diseases Pfizer Ignite will also provide strategic advisory support for Acepodia's ongoing clinical programs, ACE1831 in NHL and ACE2016 in solid tumors Acepodia's lead ACC platform therapy has shown clinical benefits...
Frost Radar™ Positions 14 Top Growth & Innovation Leaders in Global Healthcare Data Interoperability
Frost & Sullivan's Benchmarking System Highlights Leading Companies Poised for Growth and Advancing Healthcare Interoperability SAN ANTONIO, Sept. 4, 2024 /PRNewswire/ -- The healthcare data interoperability market is expected to reach $19.28 billion by 2028, growing at a compound annual growth rate (CAGR) of 18.3% from 2023. This rapid expansion is fuelled by regulatory pressures urging payers...
Immune Phenotyping Identified as Promising Predictive Biomarker by Lunit AI in Biliary Tract Cancer – New publication in CCR
AI-based tumor microenvironment classification utilizing Lunit SCOPE IO® shows promise for guiding treatment decisions in advanced BTC SEOUL, South Korea, Sept. 3, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced that Lunit SCOPE IO® has demonstrated significant potential in predicting immunotherapy...
Albatroz Therapeutics Soars into Johnson & Johnson Innovation – JLABS Singapore
SINGAPORE, Sept. 3, 2024 /PRNewswire/ -- Albatroz Therapeutics, a biotechnology company developing novel therapies against cancer and other indications, today announced its membership of Johnson & Johnson Innovation – JLABS Singapore. "We are thrilled to join the vibrant life science community at JLABS," said Dr. Frederic Bard, CEO of Albatroz Therapeutics. "This membership provides Albatroz with invaluable access to...
